F2G Biotech

F2G is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for life-threatening fungal infections. The company has pioneered a novel class of antifungals known as orotomides, which feature a distinct mechanism of action from existing therapies by targeting the fungal enzyme dihydroorotate dehydrogenase. Its lead candidate, olorofim, is currently in Phase 3 development for invasive aspergillosis and other rare, hard-to-treat mold infections. F2G aims to address the significant unmet medical need caused by increasing resistance to current antifungal standards of care. The company is headquartered in the UK with additional operations in Austria and the US. Through strategic partnerships, F2G is working to bring its novel therapies to patients globally.